Kodiak Sciences Expands Development Pipeline with Treatment of First Patient in Phase 1 Clinical Study of KSI-501, an Investigational Bispecific Antibody Biopolymer Conjugate for Retinal Diseases

/PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative...

Related Keywords

United States ,Phoenix ,Arizona ,Markr Barakat ,Jason Ehrlich ,Kodiak Sciences ,Nasdaq ,Kodiak Sciences Inc ,Prnewswire Kodiak Sciences Inc ,Antibody Biopolymer Conjugate ,Retinal Research Institute ,Retinal Consultants ,Chief Medical Officer ,Chief Development Officer ,Palo Alto ,